The conundrum of B cell depletion in SLE

    loading  Checking for direct PDF access through Ovid

Abstract

Two consecutive trials of rituximab, a B-cell-depleting anti-CD20 monoclonal antibody, have threatened the future of B-cell-targeted therapy for systemic lupus erythematosus (SLE). While rumors of the demise of this approach might be greatly exaggerated, the outcomes of these studies should force academics and the pharmaceutical industry back to the drawing board.

Related Topics

    loading  Loading Related Articles